CLL Lab Tests Revealed: Navigating Care with Confidence
Join us on Thursday, August 14, 2025 at 3pm PDT | 6pm EDT (U.S.)
For many living with CLL, lab tests are a constant part of the experience—but understanding what they mean isn’t always easy. In this in-depth conversation, CLL expert Dr. Adam Kittai joins longtime patient advocate Michele Nadeem-Baker to explore how blood tests guide real-world care decisions.
From identifying when “watch and wait” should shift to active treatment, to interpreting genetic markers like IGHV and TP53, to understanding MRD testing and remission—this discussion helps demystify what’s behind the numbers and how they shape your care.
Topics:
How ongoing blood tests guide CLL monitoring and treatment timing
What genetic tests like IGHV, TP53, and FISH reveal about your prognosis
How MRD (minimal residual disease) testing is used to assess remission
Differences in follow-up for time-limited vs. continuous treatment
Questions to ask about your labs—and what they mean for your future care
Thank you to The Leukemia & Lymphoma Society for their partnership. The Leukemia & Lymphoma Society is here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.
Register for this informative program then invite a Friend or Care Partner.
Whether you’ve just been diagnosed or have been living with CLL for years, this conversation is for you.
